Work

The CO.33/BATTMAN trial: A phase 3 randomized study of botensilimab + balstilimab versus best supportive care in chemorefractory unresectable colorectal adenocarcinoma that is not dMMR/MSI-H.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.tps3676

Authors: Jonathan M. Loree, Jeanne Tie, Emmanuelle Samalin, Sharlene Gill, Benny Johnson, Joseph Elan Grossman, Steven O'Day, Eric Xueyu Chen, Christos Stelios Karapetis, Christelle De La Fouchardiere, Winson Y. Cheung, Kelvin K. Chan, Catherine Rutledge, Dongsheng Tu, Christopher J. O'Callaghan

Institutions: BC Cancer Agency, University of British Columbia, Peter MacCallum Cancer Centre, Agenus (United States), Princess Margaret Cancer Centre, Flinders Medical Centre, Institut Paoli-Calmettes, University of Calgary, Sunnybrook Health Science Centre, Sunnybrook Hospital, Odette Cancer Centre, Canadian Cancer Trials Group, Queen's University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162697678

Cites:

Cited by:

Related to: